Black Diamond Therapeutics Inc Total Liabilities
Black Diamond Therapeutics Inc total liabilities. Based on the latest financial reports, Black Diamond Therapeutics Inc (BDTX) has total liabilities worth $28.94 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Black Diamond Therapeutics Inc (BDTX) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Black Diamond Therapeutics Inc (2017–2025)
Total liabilities of Black Diamond Therapeutics Inc from 2017 to 2025. This chart illustrates how Black Diamond Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Black Diamond Therapeutics Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Black Diamond Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Black Diamond Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fino Payments Bank Limited
NSE:FINOPB
|
India | Rs-7.47 Billion |
|
Twinhead International Corp
TW:2364
|
Taiwan | NT$1.09 Billion |
|
Akenerji Elektrik Uretim AS
IS:AKENR
|
Turkey | TL24.73 Billion |
|
ELK-Desa Resources Bhd
KLSE:5228
|
Malaysia | RM403.47 Million |
|
Waldencast Acquisition Corp
NASDAQ:WALD
|
USA | $316.10 Million |
|
Triple i Logistics Public Company Limited
BK:III
|
Thailand | ฿1.01 Billion |
|
Velo3D, Inc.
NASDAQ:VELO
|
USA | $63.74 Million |
|
HE Group Berhad
KLSE:0296
|
Malaysia | RM50.76 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Black Diamond Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Black Diamond Therapeutics Inc's balance sheet.
Liquidity & Leverage Metrics
Black Diamond Therapeutics Inc Total Liabilities Ratios Explained
Black Diamond Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Black Diamond Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Black Diamond Therapeutics Inc (2017–2025)
The table below shows the annual total liabilities of Black Diamond Therapeutics Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $30.80 Million | -21.74% |
| 2024-12-31 | $39.35 Million | -5.92% |
| 2023-12-31 | $41.83 Million | +3.13% |
| 2022-12-31 | $40.56 Million | -21.67% |
| 2021-12-31 | $51.78 Million | +136.32% |
| 2020-12-31 | $21.91 Million | -89.33% |
| 2019-12-31 | $205.45 Million | +204.97% |
| 2018-12-31 | $67.37 Million | +358.41% |
| 2017-12-31 | $14.70 Million | -- |
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutan… Read more